肝病

订阅

MedSci主页 / 所有栏目 / 肝病

Gut Liver：Daclatasvir联合Asunaprevir治疗HCV基因1b型患者的疗效和安全性

2018-02-11 MedSci MedSci原创

DaclatasvirasunaprevirHCV肝纤维化疗效安全
关注

研究结论：DCV联合ASV治疗获得了较高的SVR12，并改善了患者肝纤维化程度；联合治疗在基因1b型丙型肝炎病毒感染患者中，治疗效果良好。

研究背景：Daclatasvir联合asunaprevir(DCV+ASV)在治疗HCV 1b型患者，有强大的抗病毒作用。本研究的目的是在韩国HCV基因1b患者中探讨DCV+ASV治疗的真实效果和作用。

研究方法：本研究纳入2015年8月至2017年1月，采用DCV联合ASV治疗的363例HCV患者。本研究最终纳入治疗结束后，随访12周的270例患者。

研究结果：270例患者的平均年龄为60.7岁，女性患者占总人数的60.4%。64.8%的患者为初治患者，56例患者(20.7%)为肝硬化患者。257例患者(95.2%)和251例患者(93.0%)分别获得了结束后治疗反应和治疗后12周可持续病毒学反应(SVR12)。年龄为65岁、男性、无肝硬化、HCV RNA载量较低的患者SVR12反应率较高。基线肝硬化指数和fibrosis-4以及天冬氨酸氨基转移酶/血小板指数到SVR12评估时间时，指数都减低了。

研究结论：DCV联合ASV治疗获得了较高的SVR12，并改善了患者肝纤维化程度；联合治疗在基因1b型丙型肝炎病毒感染患者中，治疗效果良好。

原始出处

Lee HW， Oh SR， Kim DY， et al. Daclatasvir Plus Asunaprevir for the Treatment of Patients with Hepatitis C Virus Genotype 1b Infection： Real-World Efficacy， Changes in Liver Stiffness and Fibrosis Markers， and Safety. Gut Liver， 2018， Feb 8. doi： 10.5009/gnl17298.

本文系梅斯医学（MedSci）原创编译整理，转载需授权！


版权声明：
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料，版权均属于梅斯医学所有。非经授权，任何媒体、网站或个人不得转载，授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章，或“梅斯号”自媒体发布的文章，仅系出于传递更多信息之目的，本站仅负责审核内容合规，其内容不代表本站立场，本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系，我们将立即进行删除处理。
在此留言
评论区 (5)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1780229, encodeId=cb001e8022941, content=<a href='/topic/show?id=4c382904cd' target=_blank style='color:#2F92EE;'>#asunaprevir#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2904, encryptionId=4c382904cd, topicName=asunaprevir)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e87d405, createdName=Homburg, createdTime=Mon Dec 17 23:02:00 CST 2018, time=2018-12-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1720849, encodeId=b1cf1e2084924, content=<a href='/topic/show?id=634ee040179' target=_blank style='color:#2F92EE;'>#疗效和安全性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=70401, encryptionId=634ee040179, topicName=疗效和安全性)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=16ef32982072, createdName=经常头晕, createdTime=Sat Apr 21 01:02:00 CST 2018, time=2018-04-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1257718, encodeId=5d45125e718d5, content=<a href='/topic/show?id=774e856e22' target=_blank style='color:#2F92EE;'>#HCV#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8567, encryptionId=774e856e22, topicName=HCV)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=460849, createdName=ymljack, createdTime=Tue Feb 13 11:02:00 CST 2018, time=2018-02-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1466044, encodeId=6c09146604407, content=<a href='/topic/show?id=217c292009' target=_blank style='color:#2F92EE;'>#ATA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2920, encryptionId=217c292009, topicName=ATA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=387a6772119, createdName=bbjsj_1981, createdTime=Tue Feb 13 11:02:00 CST 2018, time=2018-02-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1587598, encodeId=6bfe158e5982f, content=<a href='/topic/show?id=419c565653' target=_blank style='color:#2F92EE;'>#Daclatasvir#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5656, encryptionId=419c565653, topicName=Daclatasvir)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=cb0d17523353, createdName=guojianrong, createdTime=Tue Feb 13 11:02:00 CST 2018, time=2018-02-13, status=1, ipAttribution=)]
    2018-12-17 Homburg

    #asunaprevir#

    0

  2. [GetPortalCommentsPageByObjectIdResponse(id=1780229, encodeId=cb001e8022941, content=<a href='/topic/show?id=4c382904cd' target=_blank style='color:#2F92EE;'>#asunaprevir#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2904, encryptionId=4c382904cd, topicName=asunaprevir)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e87d405, createdName=Homburg, createdTime=Mon Dec 17 23:02:00 CST 2018, time=2018-12-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1720849, encodeId=b1cf1e2084924, content=<a href='/topic/show?id=634ee040179' target=_blank style='color:#2F92EE;'>#疗效和安全性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=70401, encryptionId=634ee040179, topicName=疗效和安全性)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=16ef32982072, createdName=经常头晕, createdTime=Sat Apr 21 01:02:00 CST 2018, time=2018-04-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1257718, encodeId=5d45125e718d5, content=<a href='/topic/show?id=774e856e22' target=_blank style='color:#2F92EE;'>#HCV#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8567, encryptionId=774e856e22, topicName=HCV)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=460849, createdName=ymljack, createdTime=Tue Feb 13 11:02:00 CST 2018, time=2018-02-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1466044, encodeId=6c09146604407, content=<a href='/topic/show?id=217c292009' target=_blank style='color:#2F92EE;'>#ATA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2920, encryptionId=217c292009, topicName=ATA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=387a6772119, createdName=bbjsj_1981, createdTime=Tue Feb 13 11:02:00 CST 2018, time=2018-02-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1587598, encodeId=6bfe158e5982f, content=<a href='/topic/show?id=419c565653' target=_blank style='color:#2F92EE;'>#Daclatasvir#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5656, encryptionId=419c565653, topicName=Daclatasvir)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=cb0d17523353, createdName=guojianrong, createdTime=Tue Feb 13 11:02:00 CST 2018, time=2018-02-13, status=1, ipAttribution=)]
    2018-04-21 经常头晕

    #疗效和安全性#

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=1780229, encodeId=cb001e8022941, content=<a href='/topic/show?id=4c382904cd' target=_blank style='color:#2F92EE;'>#asunaprevir#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2904, encryptionId=4c382904cd, topicName=asunaprevir)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e87d405, createdName=Homburg, createdTime=Mon Dec 17 23:02:00 CST 2018, time=2018-12-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1720849, encodeId=b1cf1e2084924, content=<a href='/topic/show?id=634ee040179' target=_blank style='color:#2F92EE;'>#疗效和安全性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=70401, encryptionId=634ee040179, topicName=疗效和安全性)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=16ef32982072, createdName=经常头晕, createdTime=Sat Apr 21 01:02:00 CST 2018, time=2018-04-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1257718, encodeId=5d45125e718d5, content=<a href='/topic/show?id=774e856e22' target=_blank style='color:#2F92EE;'>#HCV#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8567, encryptionId=774e856e22, topicName=HCV)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=460849, createdName=ymljack, createdTime=Tue Feb 13 11:02:00 CST 2018, time=2018-02-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1466044, encodeId=6c09146604407, content=<a href='/topic/show?id=217c292009' target=_blank style='color:#2F92EE;'>#ATA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2920, encryptionId=217c292009, topicName=ATA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=387a6772119, createdName=bbjsj_1981, createdTime=Tue Feb 13 11:02:00 CST 2018, time=2018-02-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1587598, encodeId=6bfe158e5982f, content=<a href='/topic/show?id=419c565653' target=_blank style='color:#2F92EE;'>#Daclatasvir#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5656, encryptionId=419c565653, topicName=Daclatasvir)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=cb0d17523353, createdName=guojianrong, createdTime=Tue Feb 13 11:02:00 CST 2018, time=2018-02-13, status=1, ipAttribution=)]
    2018-02-13 ymljack

    #HCV#

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=1780229, encodeId=cb001e8022941, content=<a href='/topic/show?id=4c382904cd' target=_blank style='color:#2F92EE;'>#asunaprevir#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2904, encryptionId=4c382904cd, topicName=asunaprevir)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e87d405, createdName=Homburg, createdTime=Mon Dec 17 23:02:00 CST 2018, time=2018-12-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1720849, encodeId=b1cf1e2084924, content=<a href='/topic/show?id=634ee040179' target=_blank style='color:#2F92EE;'>#疗效和安全性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=70401, encryptionId=634ee040179, topicName=疗效和安全性)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=16ef32982072, createdName=经常头晕, createdTime=Sat Apr 21 01:02:00 CST 2018, time=2018-04-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1257718, encodeId=5d45125e718d5, content=<a href='/topic/show?id=774e856e22' target=_blank style='color:#2F92EE;'>#HCV#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8567, encryptionId=774e856e22, topicName=HCV)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=460849, createdName=ymljack, createdTime=Tue Feb 13 11:02:00 CST 2018, time=2018-02-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1466044, encodeId=6c09146604407, content=<a href='/topic/show?id=217c292009' target=_blank style='color:#2F92EE;'>#ATA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2920, encryptionId=217c292009, topicName=ATA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=387a6772119, createdName=bbjsj_1981, createdTime=Tue Feb 13 11:02:00 CST 2018, time=2018-02-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1587598, encodeId=6bfe158e5982f, content=<a href='/topic/show?id=419c565653' target=_blank style='color:#2F92EE;'>#Daclatasvir#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5656, encryptionId=419c565653, topicName=Daclatasvir)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=cb0d17523353, createdName=guojianrong, createdTime=Tue Feb 13 11:02:00 CST 2018, time=2018-02-13, status=1, ipAttribution=)]
    2018-02-13 bbjsj_1981

    #ATA#

    0

  5. [GetPortalCommentsPageByObjectIdResponse(id=1780229, encodeId=cb001e8022941, content=<a href='/topic/show?id=4c382904cd' target=_blank style='color:#2F92EE;'>#asunaprevir#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2904, encryptionId=4c382904cd, topicName=asunaprevir)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e87d405, createdName=Homburg, createdTime=Mon Dec 17 23:02:00 CST 2018, time=2018-12-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1720849, encodeId=b1cf1e2084924, content=<a href='/topic/show?id=634ee040179' target=_blank style='color:#2F92EE;'>#疗效和安全性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=70401, encryptionId=634ee040179, topicName=疗效和安全性)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=16ef32982072, createdName=经常头晕, createdTime=Sat Apr 21 01:02:00 CST 2018, time=2018-04-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1257718, encodeId=5d45125e718d5, content=<a href='/topic/show?id=774e856e22' target=_blank style='color:#2F92EE;'>#HCV#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8567, encryptionId=774e856e22, topicName=HCV)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=460849, createdName=ymljack, createdTime=Tue Feb 13 11:02:00 CST 2018, time=2018-02-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1466044, encodeId=6c09146604407, content=<a href='/topic/show?id=217c292009' target=_blank style='color:#2F92EE;'>#ATA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2920, encryptionId=217c292009, topicName=ATA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=387a6772119, createdName=bbjsj_1981, createdTime=Tue Feb 13 11:02:00 CST 2018, time=2018-02-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1587598, encodeId=6bfe158e5982f, content=<a href='/topic/show?id=419c565653' target=_blank style='color:#2F92EE;'>#Daclatasvir#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5656, encryptionId=419c565653, topicName=Daclatasvir)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=cb0d17523353, createdName=guojianrong, createdTime=Tue Feb 13 11:02:00 CST 2018, time=2018-02-13, status=1, ipAttribution=)]
    2018-02-13 guojianrong

    #Daclatasvir#

    0

相关资讯

Eur J Gastroenterol Hepatol：Sofosbuvir、daclatasvir联合利巴韦林治疗改善慢性丙型肝炎患者肝功能

总之，研究结果表明，SOF、DCV等直接抗病毒药物联合利巴韦林治疗显著改善了慢性丙型肝炎患者肝脏功能和临床治疗效果。

超级重磅！百时美全口服丙肝鸡尾酒daclatasvir+asunaprevir中国丙肝III期临床获得成功

百时美施贵宝（BMS）近日在日本东京举行的2016年亚太肝脏研究学会年会（APASL 2016）上公布了在中国丙肝患者中成功完成的有关全口服丙肝鸡尾酒（daclatasvir+asunaprevir）的首个III期临床研究的数据。该研究调查了全口服丙肝鸡尾酒24周治疗方案在亚洲（非日本）基因型1b丙肝患者中的疗效和安全性。数据显示，该全口服丙肝鸡尾酒24周方案取得了非常高的治愈率。在中国，基因型1

功亏一篑！FDA推迟施贵宝丙肝药物daclatasvir上市

常言道行百里者半九十。想必生物医药公司在经历大量繁琐的临床研究后，将所有数据提交给审批部门时就是这种心情。最近，制药巨头施贵宝公司就经历了这样的大起大落。 美国FDA在审核施贵宝公司提交的治疗丙肝药物daclatasvir相关数据后，认为施贵宝公司仍然需要补充更多数据，因而暂缓批准davlatasvir上市的请求。Daclatasvir是一种NS5A抑制剂。施贵宝公司和FDA并未透露过多细节

Lancet Infect ：慢性丙型肝炎治疗进展-Daclatasvir

文献标题：Daclatasvir for previously untreated chronic hepatitis C genotype-1 infection: a randomised, parallel-group, double-blind, placebo-controlled, dose-finding, phase 2a trial.文献来源： Lancet Infect Dis

Liver Int：Daclatasvir治疗CHC患者疗效显著

总之，研究表明，daclatasvir治疗后，99%的患者达到的可持续病毒学应答状态能够持续。肝脏疾病进展和新发肝细胞癌的病例少见。NS5A替换在非应答患者中的持续时间超过NS3替换。